These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37341835)

  • 1. Relations between nonmotor manifestations and motor disorders in patients with benign essential blepharospasm.
    Zhou Y; Wang W; Lin Z; Lin T; Gong L
    Graefes Arch Clin Exp Ophthalmol; 2023 Dec; 261(12):3615-3623. PubMed ID: 37341835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
    Lu R; Huang R; Li K; Zhang X; Yang H; Quan Y; Li Q
    Am J Ophthalmol; 2014 Mar; 157(3):591-7.e1-2. PubMed ID: 24269849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm.
    Bayraktar Bilen N; Bilen Ş; Topçu Yılmaz P; Evren Kemer Ö
    Int Ophthalmol; 2022 Aug; 42(8):2625-2632. PubMed ID: 35355169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
    Ho RW; Fang PC; Chao TL; Chien CC; Kuo MT
    Sci Rep; 2018 May; 8(1):8367. PubMed ID: 29849166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tear osmolarity, dry eye syndrome, blepharospasm and botulinum neurotoxin.
    Girard B; de Saint Sauveur G
    J Fr Ophtalmol; 2021 Dec; 44(10):1553-1559. PubMed ID: 34756743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB.
    Isshiki Y; Ishikawa H; Mimura O
    Jpn J Ophthalmol; 2016 Nov; 60(6):486-491. PubMed ID: 27503401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
    Park DI; Shin HM; Lee SY; Lew H
    Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
    Hosotani Y; Yokoi N; Okamoto M; Ishikawa H; Komuro A; Kato H; Mimura O; Gomi F
    Jpn J Ophthalmol; 2020 Jan; 64(1):45-53. PubMed ID: 31823132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
    Horwath-Winter J; Bergloeff J; Floegel I; Haller-Schober EM; Schmut O
    Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dry eye and qualitative tear alteration in essential blepharospasm].
    Girard B; Begnaud S
    J Fr Ophtalmol; 2022 Mar; 45(3):288-297. PubMed ID: 35148903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
    Saad J; Gourdeau A
    J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between various clinical outcome assessments in patients with blepharospasm.
    Jankovic J; Kenney C; Grafe S; Goertelmeyer R; Comes G
    Mov Disord; 2009 Feb; 24(3):407-13. PubMed ID: 19053054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection.
    Kocabeyoglu S; Sekeroglu HT; Mocan MC; Muz E; Irkec M; Sanac AS
    Eur J Ophthalmol; 2014; 24(6):830-4. PubMed ID: 24803156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Sleep Quality, Mood Status, and Ocular Surface Characteristics in Patients With Dry Eye Disease.
    Wu M; Liu X; Han J; Shao T; Wang Y
    Cornea; 2019 Mar; 38(3):311-317. PubMed ID: 30614900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum Neurotoxin Type a Injection Combined with Absorbable Punctal Plug Insertion: An Effective Therapy for Blepharospasm Patients with Dry Eye.
    Ndikumukiza M; Xiao YT; Ye YF; Wang JS; Peng X; Xie HT; Zhang MC
    J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dry eye syndrome in benign essential blepharospasm.
    Girard BC; Lévy P
    J Fr Ophtalmol; 2019 Dec; 42(10):1062-1067. PubMed ID: 31733914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines.
    Choi MG; Yeo JH; Kang JW; Chun YS; Lee JK; Kim JC
    Graefes Arch Clin Exp Ophthalmol; 2019 Feb; 257(2):331-338. PubMed ID: 30552510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular Surface Metrics in Blepharospasm Patients After Treatment With Botulinum Toxin Injections.
    Yabumoto C; Osaki MH; Osaki T; Gameiro GR; Campos M; Osaki TH
    Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):475-478. PubMed ID: 36928309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Two Botulinum Neurotoxin A Injection Patterns with or without the Medial Lower Eyelid in the Treatment of Blepharospasm.
    Yang H; Lu J; Zhao X; Ding X; Wang Z; Cai X; Luo Y; Lu L
    J Ophthalmol; 2016; 2016():5957812. PubMed ID: 26885381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
    Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
    Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.